Atai Life Sciences (ATAI) said late Monday it has closed its public offering of around 27.3 million shares, including the full exercise of an over-allotment option, raising about $149.5 million.
The clinical-stage biopharmaceutical company said it expects its funds will be sufficient to cover its operations into 2029.
Shares of the company were up about 2% in after-hours activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.